Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Nat Immunol. 2011 Aug 7;12(9):844–852. doi: 10.1038/ni.2080

Figure 3. IKKi is required for IL-17-mediated pulmonary inflammation.

Figure 3

A. Total BAL and differential cell count were analyzed in samples from control or IL-17 challenged (1 µg through intranasal injection for 24 h) wild-type and IKKi-deficient mice (n=6) P<0.05. Cytospins prepared from the BAL of control or IL-17 challenged wild-type and IKKi-deficient mice were stained with Hema3, and differential cell counting was performed using standard morphological criteria. Magnification x400.

B. The lung sections from control or IL-17 challenged wild-type and IKKi-deficient mice (1 µg through intranasal injection for 24 h) were stained with H&E. Magnification x100.

C. ELISA of CXCL1 chemokine in BAL fluid from control or IL-17 challenged wild-type and IKKi-deficient mice.

D. Real-time PCR analysis of CXCL1, TNF, CXCL2, IL-6 and CSF3 in the lung tissues from control or IL-17 treated wild-type and IKKi-deficient mice. Expression of mRNA is presented as arbitrary units (mean ± s.d.) relative to the expression of mRNA encoding β-Actin. P<0.05.

The data shown in this figure are representation of two independent experiments.